Chempaq secures investment to bring new measuring instrument to market  

The Danish medicotech company has received a DKK 41 million investment from two new and three existing investors

The Danish medicotech company Chempaq has secured a DKK 41 million (USD 6.6 million) investment from two new and three existing investors. The money will be used to bring Chempaq's revolutionary new blood analysis instrument Chempaq XBC (eXpress Blood Count) to market later this year. The Finland based BioFund and the Danish venture company Vecata are the two new investors, while the existing investors are Symbion Capital, the Danish Fund for Industrial Growth and InnFond.


Chempaq’s analyzer technology is built around a sensor which enables easy-to-perform diagnostics on a blood drop from the fingertip. The analyzer is only the size of a cigar box, while conventional measuring instruments in hospitals are large and expensive. Chempaq XPC can give almost immediate answers and is easy to use by e.g. general practitioners. Consequently patients can get much more rapid test results than with current practice. The news is reported by the professional journal Ingeniøren (the Engineer).


Chempaq was founded in 1999 as a spin-out from the Micro Electronics Center at the Technical University of Denmark. The company is located in Symbion Science Park in Copenhagen and employs 17 people.


Link > Chempaq

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×